Screener
Tarsus Pharmaceuticals, Inc. TARS Business Segments — Other reconciling items
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 60,695 | 37,156 | 112,642 | 61,865 |
| Total operating expenses | 193,820 | 124,844 | 361,996 | 229,459 |
| Loss from operations | (19,908) | (22,184) | (26,030) | (48,464) |
| Other reconciling items(1) | 1,357 | 1,844 | 512 | 3,004 |
| Net loss | $(18,551) | $(20,340) | $(25,518) | $(45,460) |
| Other segment disclosures: | ||||
| Interest income | $3,698 | $4,229 | $7,420 | $7,683 |
| Interest expense | $(2,156) | $(2,240) | $(4,284) | $(4,453) |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — other reconciling items of $1.36M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items decreased by 26.4% year-over-year, from $1.84M to $1.36M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items has grown at a 99.7% compound annual growth rate (CAGR), from $621K to $4.95M.
- What does business segments — other reconciling items mean?
- Includes non-recurring or peripheral financial adjustments that are not directly attributable to the core operating activities of the business segment. These items are necessary to reconcile segment performance with the overall consolidated financial statements.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — other reconciling items.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude